Related Topics
 
Vasiliki (Vicky) Leventaki, MD

Vasiliki Leventaki, MD

Research Associate, St. Jude Faculty

Departments

Pathology

Contact Information

Vasiliki Leventaki, MD
Pathology
MS 342, Room D4047E
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: vasiliki.leventaki@stjude.org
Phone: (901) 595-7531
FAX: (901) 595-5947

Education

MD - National and Kapodistrian University of Athens, Athens, Greece
Residency - Anatomic and Clinical, University of Utah
Fellowship - Hematopathology, UT MD Anderson Cancer Center


Research Interests


Selected Publications

Leventaki V*, Rodic V, Tripp SR, Bayerl MG, Perkins SL, Barnette P, Schiffman JD, Miles RR. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. Br J Haematol 158(6):763-771, 2012. *This work was partially supported by a Resident Research Grant from the College of American Pathologists Foundation.

Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymph 53(9):1839-1841, 2012.

Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, Vega F, Miranda RN, Claret FX, Medeiros LJ, Rassidakis GZ. Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas. Hum Pathol 42(8):1117-1124, 2011.

Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 29(46):6125-6137, 2010.

Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, Staikou-Drakopoulou E, Patsouris E, Panayiotidis P, Medeiros LJ, Rassidakis GZ. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer 9:292, 2010.

Inamdar KV, Romaguera JE, Drakos E, Knoblock RJ, Garcia M, Leventaki V, Medeiros LJ, Rassidakis GZ. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine. Cancer 115(20):4727-4736, 2009.

Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE. Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer 115(23):5481-5489, 2009.

Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, Rassidakis GZ. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 23(4):784-790, 2009.

Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 13(11):3380-3387, 2007.

Leventaki V, Drakos E, Lim SM, Elenitoba-Johnson SK, Claret FX, Medeiros LJ, Rassidakis GZ. NPM-ALK oncogenic kinase promotes cell cycle progression through activation of JNK/cJun in anaplastic large cell lymphoma. Blood 110(5):1621-1630, 2007.

Peponi E*, Drakos E*, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ (*equal contribution). Activation of mTOR signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169(6):2171-2180, 2006.

Drakos E, Leventaki V, Schlette EJ, Jones D, Lin P, Medeiros LJ, Rassidakis GZ. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders. Am J Surg Pathol 31(3):447-453, 2006.

Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret F-X, Rassidakis GZ. Activation of mTOR Signaling Pathway Contributes to Tumor Cell Survival in ALK+ anaplastic large cell lymphoma. Cancer Res 66(13):6589-6597, 2006.

Oyarzo MP, Medeiros LJ, Atwell C, Feretzaki M, Leventaki V, Wang S, Drakos E, Amin HM, Rassidakis GZ. c-FLIP Confers Resistance to Fas-mediated apoptosis in anaplastic large cell lymphoma. Blood 107(6):2544-2537, 2006.

Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23(32):5426-5434, 2004.

Amin H, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V, Rassidakis GZ, O’Connor SL, McDonnell TJ, LaiR. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 22(35):5399-5407, 2003.

Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, McDonnell TJ. Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumors. J Pathol 199(1):84-89, 2003.

Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin HM, Lai R. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 9(10):3692-3699, 2003.

Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, Keating MJ, Lai R. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 127(4):424-431, 2003.


Last update: August 2013